Health Care & Life Sciences » Biotechnology | Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
66,122.00
15,000.00
-
1,158
Cost of Goods Sold (COGS) incl. D&A
399.00
489.00
-
-
1,126.00
1,158
Gross Income
399.00
489.00
-
-
1,126.00
1,158
SG&A Expense
59,078.00
69,615.00
81,175.00
79,321.00
88,315.00
73,088
EBIT
59,477.00
70,104.00
15,747.00
65,276.00
89,441.00
74,246
Unusual Expense
-
-
8,944.00
-
-
1,900
Interest Expense
52.00
37.00
55.00
68.00
50.00
36
Pretax Income
58,947.00
69,686.00
5,670.00
62,117.00
85,101.00
70,504
Income Tax
-
678.00
640.00
411.00
135.00
232
Consolidated Net Income
58,947.00
69,008.00
5,030.00
61,706.00
85,236.00
70,272
Net Income
58,947.00
69,008.00
5,030.00
61,706.00
85,236.00
70,272
Net Income After Extraordinaries
58,947.00
69,008.00
5,030.00
61,706.00
85,236.00
70,272
Net Income Available to Common
58,947.00
69,008.00
5,030.00
61,706.00
85,236.00
70,272
EPS (Basic)
0.63
0.70
0.04
0.45
0.62
0.51
Basic Shares Outstanding
93,983.00
98,367.00
125,592.00
136,667.00
137,180.00
138,418
EPS (Diluted)
0.63
0.70
0.04
0.45
0.62
0.51
Diluted Shares Outstanding
93,983.00
98,367.00
125,592.00
136,667.00
137,180.00
138,418
EBITDA
59,078.00
69,615.00
15,053.00
64,321.00
88,315.00
73,088
Non-Operating Interest Income
582.00
455.00
1,188.00
3,227.00
4,390.00
5,678

About Achillion Pharmaceuticals

View Profile
Address
VEVA Building 14
Blue Bell Pennsylvania 19422
United States
Employees -
Website http://www.achillion.com
Updated 07/08/2019
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.